Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guangbin Yang

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Molecular Pharmaceutics|November 14, 2013
Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapySarah M Cheal, Barney Yoo, Sarah Boughdad, et al.
Bioconjugate Chemistry|January 1, 2020
An <i>N</i>-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted RadioimmunotherapySarah M Cheal, Mitesh Patel, Guangbin Yang, et al.
Cancers|April 26, 2016
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First RemissionRoisin E O'Cearbhaill, Govind Ragupathi, Jianglong Zhu, et al.
Theranostics|June 16, 2025
GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancerAlexandre B Le Roux, Edward K Fung, Sang Gyu Lee, et al.
Science (New York, N.Y.)|June 18, 2016
Improvements in ecosystem services from investments in natural capitalZhiyun Ouyang, Hua Zheng, Yi Xiao, et al.
The Journal of Clinical Investigation|September 21, 2010
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansSachie Marubayashi, Priya Koppikar, Tony Taldone, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 12, 2026
Preclinical <sup>203/212</sup>Pb-DOTA-Based Pretargeted Radioimmunotherapy in Nude Mice Bearing Established Human Colorectal Cancer XenograftsBrett A Vaughn, Darren R Veach, Daniela Burnes Vargas, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted RadioimmunotherapyBrian H Santich, Sarah M Cheal, Mahiuddin Ahmed, et al.
Cancer Research|June 4, 2016
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome InhibitorsNeerav Shukla, Romel Somwar, Roger S Smith, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Molecular Pharmaceutics|November 14, 2013
Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapySarah M Cheal, Barney Yoo, Sarah Boughdad, et al.
Bioconjugate Chemistry|January 1, 2020
An <i>N</i>-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted RadioimmunotherapySarah M Cheal, Mitesh Patel, Guangbin Yang, et al.
Cancers|April 26, 2016
A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First RemissionRoisin E O'Cearbhaill, Govind Ragupathi, Jianglong Zhu, et al.
Theranostics|June 16, 2025
GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancerAlexandre B Le Roux, Edward K Fung, Sang Gyu Lee, et al.
Science (New York, N.Y.)|June 18, 2016
Improvements in ecosystem services from investments in natural capitalZhiyun Ouyang, Hua Zheng, Yi Xiao, et al.
The Journal of Clinical Investigation|September 21, 2010
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansSachie Marubayashi, Priya Koppikar, Tony Taldone, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 12, 2026
Preclinical <sup>203/212</sup>Pb-DOTA-Based Pretargeted Radioimmunotherapy in Nude Mice Bearing Established Human Colorectal Cancer XenograftsBrett A Vaughn, Darren R Veach, Daniela Burnes Vargas, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted RadioimmunotherapyBrian H Santich, Sarah M Cheal, Mahiuddin Ahmed, et al.
Cancer Research|June 4, 2016
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome InhibitorsNeerav Shukla, Romel Somwar, Roger S Smith, et al.
Pageof 4